GlassScriptPhysician profile
Cynthia Folk
NPI 1356678296
$1,877.28
in general payments reported to CMS, 2019-2025
18 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $87.96 · 2022: $262 · 2023: $710 · 2024: $381 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,397.08 |
| Education | $130.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $537.68 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan |
| Pfizer INC. | $332.62 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $218.31 | 2022-2025 | Eliquis, Camzyos |
| Amgen INC. | $181.20 | 2021-2025 | Repatha, Repatha |
| Lexicon Pharmaceuticals, INC. | $115.91 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $103.44 | 2023-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $61.71 | 2022-2024 | Xarelto |
| Itamar Medical INC | $41.29 | 2022 | |
| Novartis Pharmaceuticals Corporation | $39.32 | 2022 | |
| Daiichi Sankyo INC. | $38.76 | 2023 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $38.68 | 2022-2024 | Uptravi, Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.10 | 2024-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $33.78 | 2025 | Amvuttra |
| Lemaitre Vascular, INC. | $32.50 | 2025 | Hydro Lemaitre Valvulotome |
| Kiniksa Pharmaceuticals International, Plc | $26.38 | 2024 | Arcalyst |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $15.02 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.88 | 2023 | Jardiance |
| Boston Scientific Corporation | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cynthia Folk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.